Prothena up on pact with Walgreens for Alzheimer's drug trial

Prothena

13/04/2023 15:46

** Shares of biotech firm Prothena Corp  PRTA.O  up ~4% at
$51.2
    ** PRTA and drugstore chain Walgreens Boot Alliance Inc
 WBA.O  collaborate for the early-stage trial of Prothena's
ongoing, experimental Alzheimer's drug, PRX-012 
    ** Under the pact, WBA  will leverage its national footprint
to match patient populations in PRX012's trial
    ** PRTA's drug also holds U.S. FDA's fast track designation;
the health agency's tag facilitates the development and expedite
the review of drug candidates intended to treat serious
conditions 
    ** Topline trial data from PRTA's single and multiple
ascending dose studies expected by year end 2023
    ** Including session's gain, PRTA stock down ~15% YTD
    

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))